Clinical Trials — Hematologic Malignancies

                                                                                            Click on trial for description and contact information.

Safety and Efficacy of Panobinostat in Primary Myelofibrosis

 

Aggressive Systemic Mastocytosis or Mast Cell Leukemia

 

Phase II Study of Oral Panobinostat in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma

 

A Phase IA/II Two-Arm, Multi-Center, Open-Label, Dose-Escalation Study of LBH589 Administered Orally via Different Dosing Schedules in Adult Patients with Advanced Hematological Malignancies (This study is ongoing but is no longer recruiting participants.)

 

A Phase 2, multi-center, open-label, exploratory study of Bcr-Abl kinetics in adult patients on nilotinib with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) and a suboptimal molecular response to imatinib

     

A single arm, phase II, open-label study to determine the efficacy of 100mg twice daily oral dosing of Midostaurin administered to patients with Aggressive Systemic Mastocytosis or Mast Cell Leukemia +/- an Associated Hematological Clonal Non-Mast Cell Lineage Disease

     

A Phase I Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of SNX-5422 Mesylate in Subjects with Refractory Hematological Malignancies

     

A Phase I Open-Label, Multi-Center, Parallel Group Study to Assess the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients with and without Impaired Renal Function

 

Revised September 11, 2009.  Please send comments, suggestions or questions about this page to Cancer Team, cancer@mcg.edu.